certolizumab pegol

Ligand id: 6774

Name: certolizumab pegol

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: certolizumab pegol

References
1. Choy EH, Hazleman B, Smith M, Moss K, Lisi L, Scott DG, Patel J, Sopwith M, Isenberg DA. (2002)
Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial.
Rheumatology (Oxford)41 (10): 1133-7. [PMID:12364632]
2. Nesbitt A, Fossati G, Bergin M, Stephens P, Stephens S, Foulkes R, Brown D, Robinson M, Bourne T. (2007)
Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents.
Inflamm. Bowel Dis.13 (11): 1323-32. [PMID:17636564]
3. Song IH, Rudwaleit M. (2013)
Certolizumab pegol in axial spondyloarthritis.
Expert Rev Clin Immunol9 (12): 1161-72. [PMID:24215406]